ATE346912T1 - Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen- präsentierenden zellen beladen mit rna - Google Patents

Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen- präsentierenden zellen beladen mit rna

Info

Publication number
ATE346912T1
ATE346912T1 AT97922581T AT97922581T ATE346912T1 AT E346912 T1 ATE346912 T1 AT E346912T1 AT 97922581 T AT97922581 T AT 97922581T AT 97922581 T AT97922581 T AT 97922581T AT E346912 T1 ATE346912 T1 AT E346912T1
Authority
AT
Austria
Prior art keywords
rna
antigen
treating cancer
presenting cells
cells loaded
Prior art date
Application number
AT97922581T
Other languages
German (de)
English (en)
Inventor
Smita K Nair
David J Boczkowski
Eli Gilboa
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE346912T1 publication Critical patent/ATE346912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
AT97922581T 1996-04-30 1997-04-30 Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen- präsentierenden zellen beladen mit rna ATE346912T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/640,444 US5853719A (en) 1996-04-30 1996-04-30 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA

Publications (1)

Publication Number Publication Date
ATE346912T1 true ATE346912T1 (de) 2006-12-15

Family

ID=42676767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97922581T ATE346912T1 (de) 1996-04-30 1997-04-30 Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen- präsentierenden zellen beladen mit rna

Country Status (11)

Country Link
US (9) US5853719A (Direct)
EP (3) EP2298927A3 (Direct)
JP (2) JP3836151B2 (Direct)
AT (1) ATE346912T1 (Direct)
AU (1) AU724267B2 (Direct)
CA (1) CA2253632C (Direct)
DE (1) DE69737023T2 (Direct)
DK (1) DK0918848T3 (Direct)
ES (1) ES2277675T3 (Direct)
PT (1) PT918848E (Direct)
WO (1) WO1997041210A1 (Direct)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
EP1333094B1 (en) * 1996-10-01 2012-04-04 Geron Corporation Human telomerase catalytic subunit
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US20020041868A1 (en) * 1997-04-15 2002-04-11 Charles Nicolette Cell fusions and methods of making and using the same
US20050169898A1 (en) * 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
FR2785542B1 (fr) * 1998-11-06 2001-02-09 Pf Medicament UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7015204B1 (en) * 1999-10-07 2006-03-21 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002070748A2 (en) * 2000-10-24 2002-09-12 Whitehead Institute For Biomedical Research Response of dendritic cells to a diverse set of pathogens
US20030059834A1 (en) * 2001-02-01 2003-03-27 Chang Nancy T. Methods to generate and identify monoclonal antibodies to a large number of human antigens
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
EP1390076A4 (en) * 2001-04-27 2004-12-15 Xcyte Therapies Inc Maturation of antigen-presenting cells with activated cells
GB0111015D0 (en) * 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
AU2002327614B2 (en) * 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
US20040086485A1 (en) * 2001-10-04 2004-05-06 Aguilar-Cordova Carlos Estuardo Chemeric viral vectors for gene therapy
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003253790A1 (en) * 2002-07-05 2004-01-23 Duke University Angio-immunotherapy
US20040161417A1 (en) * 2002-08-14 2004-08-19 Eli Gilboa Method of enhancing CD4+ T cell responses
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
AU2003296439B2 (en) * 2002-12-10 2009-05-07 Argos Therapeutics, Inc. In situ maturation of dendritic cells
ES2618309T3 (es) * 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
CA2509979C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
EP2557164A1 (en) 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
US20040214333A1 (en) * 2003-02-18 2004-10-28 Maxcyte, Inc. Loading of cells with antigens by electroporation
MXPA05010007A (es) * 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
US7419674B2 (en) * 2003-07-11 2008-09-02 Alpha Vax, Inc. Alpha virus-based cytomegalovirus vaccines
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
WO2005052128A2 (en) * 2003-11-25 2005-06-09 Argos Therapeutics, Inc. Mrna transfected antigen presenting cells
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
WO2005116261A2 (en) * 2004-05-24 2005-12-08 Albert Einstein College Of Medecine Of Yeshiva University Rna expression microarrays
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
EP1794327B1 (en) 2004-09-14 2016-11-30 Argos Therapeutics, Inc. Strain independent amplification of pathogens and vaccines thereto
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
GB0501129D0 (en) * 2005-01-19 2005-02-23 Ribostem Ltd Method of treatment by administration of RNA
EP2325305B1 (en) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
PT1855707E (pt) 2005-02-28 2012-05-25 Oncotherapy Science Inc Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
CN101155914B (zh) 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
HUE027330T2 (en) 2005-07-27 2016-09-28 Oncotherapy Science Inc Colon cancer related gene tom34
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
CA2649325C (en) 2006-04-14 2019-01-08 Epicentre Technologies Corporation Kits and methods for generating 5' capped rna
DK2051987T3 (en) 2006-08-18 2015-01-05 Argos Therapeutics Inc USE OF CD83 IN COMBINATION THERAPY
PL2091965T3 (pl) 2006-10-17 2013-10-31 Oncotherapy Science Inc Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1
EP2465510B1 (en) * 2006-10-19 2018-11-28 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TWI434853B (zh) 2007-04-11 2014-04-21 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
ES2670813T3 (es) 2007-06-21 2018-06-01 Alphavax, Inc. Partículas de replicón de alfavirus para uso en vacunación
CN108117584B (zh) 2007-08-20 2021-08-24 肿瘤疗法科学股份有限公司 Foxm1肽和包含foxm1肽的药剂
EP2254998B1 (en) * 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
EP2303319B1 (en) 2008-06-20 2016-10-05 Duke University Compositions, methods and kits for eliciting an immune response
ES2840750T3 (es) 2008-09-22 2021-07-07 Baylor College Medicine Métodos y composiciones para generar una respuesta inmune induciendo CD40 y adaptadores del receptor de reconocimiento de patrones
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
WO2010065876A2 (en) 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
ES2617434T3 (es) 2009-03-18 2017-06-19 Oncotherapy Science, Inc. Péptidos NEIL3 y vacunas que incluyen los mismos
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
SG10201501857YA (en) 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
TW201627003A (zh) 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
EP2557089A2 (en) 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
CA2842887C (en) 2011-08-12 2021-01-19 Oncotherapy Science, Inc. Mphosph1 peptides and vaccines including the same
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
IN2014CN03922A (Direct) 2011-10-28 2015-09-04 Oncotherapy Science Inc
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014010231A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
WO2014151960A2 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
HK1226299A1 (zh) 2013-09-24 2017-09-29 Duke University 用於诱发免疫反应的组合物、方法及工具
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
US9610358B2 (en) * 2014-04-17 2017-04-04 Marker Gene Technologies, Inc Targeted pharmacological chaperones
WO2016014613A1 (en) * 2014-07-22 2016-01-28 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
KR102489834B1 (ko) 2014-08-04 2023-01-19 온코세라피 사이언스 가부시키가이샤 Koc1-유래 펩티드 및 이를 포함하는 백신
KR20170030649A (ko) 2014-08-04 2017-03-17 온코세라피 사이언스 가부시키가이샤 Urlc10-유래 펩티드 및 이를 포함하는 백신
SG10201900879PA (en) 2014-08-04 2019-03-28 Oncotherapy Science Inc Cdca1-derived peptide and vaccine containing same
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
SG11201702191YA (en) * 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
CN107106611B (zh) * 2014-10-27 2021-11-23 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
JP2018090491A (ja) * 2015-04-01 2018-06-14 株式会社細胞治療技術研究所 癌ワクチンの製造方法、及び癌ワクチン
US11090332B2 (en) * 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
JP6666094B2 (ja) * 2015-09-15 2020-03-13 株式会社東芝 吸着支持装置、および物品把持装置
CN112940076B (zh) 2015-10-08 2025-05-02 肿瘤疗法科学股份有限公司 Foxm1衍生的肽和包含它们的疫苗
US11780934B2 (en) 2016-02-05 2023-10-10 Institut Pasteur Use of inhibitors of ADAM12 as adjuvants in tumor therapies
CA3022267A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
US11331343B2 (en) 2016-06-29 2022-05-17 Duke University Compositions and methods for activating antigen presenting cells with chimeric poliovirus
US20210069310A1 (en) * 2018-01-05 2021-03-11 Rolf Jonas Andreas NILSSON Endogenous tumor-derived circular rna and proteins thereof for use as vaccine
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
WO2025101584A1 (en) * 2023-11-06 2025-05-15 Immunitybio, Inc. Virally educated t cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US5256536A (en) 1990-11-09 1993-10-26 Syntex (U.S.A.) Inc. Nucleotide probe for Neisseria gonrrhoeae
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
JPH08502244A (ja) 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫調節ペプチド
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
DE4233430A1 (de) * 1992-10-05 1994-04-07 Basf Ag Verfahren zur Herstellung von 4-Hydroxymethyltetrahydropyran
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0863913A4 (en) 1995-08-21 2001-04-11 Univ Duke METHOD FOR RECOVERING THE DENSITY OF ANTIGENS ON ANTIGENT PRESENTING CELLS
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US6228640B1 (en) * 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6831068B2 (en) * 2002-02-13 2004-12-14 Abbott Laboratories Macrolide antibacterial compounds
DE102004055330A1 (de) 2004-11-16 2006-05-24 Bosch Rexroth Aktiengesellschaft Verfahren und Vorrichtung zum Betreiben eines Netzwerkes

Also Published As

Publication number Publication date
PT918848E (pt) 2007-03-30
US7601343B2 (en) 2009-10-13
DE69737023D1 (de) 2007-01-11
EP0918848A4 (en) 2004-05-12
JP2006254920A (ja) 2006-09-28
DE69737023T2 (de) 2007-06-28
CA2253632A1 (en) 1997-11-06
JP3836151B2 (ja) 2006-10-18
WO1997041210A1 (en) 1997-11-06
DK0918848T3 (da) 2007-04-10
CA2253632C (en) 2008-12-16
US7101705B2 (en) 2006-09-05
EP2298927A3 (en) 2012-03-21
US7105157B1 (en) 2006-09-12
US6387701B1 (en) 2002-05-14
EP2298927A2 (en) 2011-03-23
JP2000509281A (ja) 2000-07-25
JP3955311B2 (ja) 2007-08-08
US20060057130A1 (en) 2006-03-16
AU2821397A (en) 1997-11-19
US5853719A (en) 1998-12-29
US20020018769A1 (en) 2002-02-14
AU724267B2 (en) 2000-09-14
US20120288931A1 (en) 2012-11-15
US20100015108A1 (en) 2010-01-21
US8263066B2 (en) 2012-09-11
EP0918848A1 (en) 1999-06-02
EP1721987B1 (en) 2015-11-11
EP0918848B1 (en) 2006-11-29
ES2277675T3 (es) 2007-07-16
US9115360B2 (en) 2015-08-25
EP1721987A1 (en) 2006-11-15
US6670186B1 (en) 2003-12-30
US6306388B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
ATE346912T1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen- präsentierenden zellen beladen mit rna
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
DE69838106D1 (de) Expressionsklonierung in filamentösen pilzen
ATE214595T1 (de) Verfahren zur herstellung von lösungsmittelfreien nicht-kristallinen biologisch aktiven substanzen
DE69942636D1 (de) Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
DE69740002D1 (de) Tierzellen und verfahren für die replikation von influenza viren
ES2180782T3 (es) Procedimiento para la identificacion o el aislamiento de una molecula y moleculas identificadas de ese modo.
ATE535615T1 (de) Chemisch modifizierte nukleinsäuren und methode zur kopplung von nukleinsäuren an einen festen träger
ATE260971T1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE321535T1 (de) Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
DE69939903D1 (de) Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav-vektoren mit hohem titer
ATE309267T1 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
DE68914412D1 (de) Methode, System und Apparat zur Züchtung von Zellen.
TW200517403A (en) Biodegradable material and process for producing said biodegradable material
DE59608710D1 (de) Dotierverfahren zur herstellung von homoübergängen in halbleitersubstraten
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
DE60332111D1 (de) Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
AR043862A1 (es) Procedimiento para la obtencion de estirpes celulares de mastocitos a partir de tejidos de cerdo y procedimiento para la produccion de moleculas de tipo de la heparina
PT935652E (pt) Produtos de factor de crescimento de queratinocitos-2
ATE297981T1 (de) Herstellung von vakzinen unter der verwendung von hybrid-zellen
ATE413451T1 (de) Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren
PT977859E (pt) O factor neurotrofico nnt-1
DK0942978T3 (da) Fremgangsmåde til fremstilling af anafase-promoverende kompleks

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0918848

Country of ref document: EP